Clinical evaluation of the novel FAP-targeting PET tracer 68Ga-XT117 in solid tumors, its synergistic role, and comparison with 18F-FDG
68 Ga-XT117 demonstrates favorable diagnostic performance, particularly in low-metabolic tumors, with good safety and optimal imaging characteristics. The tracer shows a complementary value to 18 F-FDG in lesion detection. Further prospective studies are warranted to validate the clinical significance of the additionally detected lesions.
Authors
- Qingxiao Li (ORCID: https://orcid.org/0000-0002-0088-0373)
- Shasha Sun (ORCID: https://orcid.org/0009-0001-9065-0837)
- Ji Hu (ORCID: https://orcid.org/0009-0005-5548-5994)
- Kuan Wang (ORCID: https://orcid.org/0000-0002-3815-801X)
- Xiaojun Zhang (ORCID: https://orcid.org/0000-0002-0304-0003)
- Ruimin Wang (ORCID: https://orcid.org/0000-0002-1842-6291)
- Jing Song
- Zhihui Shen
- Jinglan Zhou
Institutions
- Chinese PLA General Hospital (CN)
- China National Pharmaceutical Group Corporation (China) (CN)
- China Academy of Chinese Medical Sciences (CN)
- Guang’anmen Hospital (CN)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1097/mnm.0000000000002019
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00